The announcement is based on three retrospective studies examining the real-world treatment of 98,654 hospitalized COVID-19 patients.
In two of the studies, remdesivir reduced patients’ mortality risk by 54 percent and 23 percent.
Remdesivir became the first FDA-approved COVID-19 treatment in October.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
